Newsletter 2020 – Issue 1; Bladder Cancer “Bladder cancer (BC) has the highest lifetime treatment costs per patient (pp) of all cancers, followed by colorectal-,…
Read More
Press Release, Lund February 5, 2020 Alpha1H shows significant promise as a new and effective cancer drug with low toxicity in a clinical bladder cancer…
Pressmeddelande, Lund 3 februari, 2020 Hamlet Pharma tillförs 12,95 miljoner SEK genom inlösen av teckningsoptioner utfärdade i samband med den riktade emissionen från den 1…
Press Release, Lund December 18, 2019 Hamlet Pharma is on track with its plans to engage in a clinical trial of Alpha1H for the treatment…
BioWorld. November 6, 2019 By Cormac Sheridan – DUBLIN – Hamlet Pharma AB is about to embark on the next phase in the clinical development…
Aktieägarna i Hamlet Pharma AB, 556568-8958, kallas härmed till årsstämma torsdagen den 21 november 2019 kl. 17.30 i Gamla Börssalen, Malmö Börshus med adress Skeppsbron…
At the end of July 2019, Hamlet Pharma announced the successful completion of the Phase I/II bladder cancer study. We now provide more detailed information…
Hamlet Pharma is proud to announce the successful outcome of the Phase I/II trial, aimed at studying the safety and efficacy of Alpha1H in patients…
The ongoing phase I/II study with 40 patients is due to complete in May/June 2019. The last study patient is expected to undergo scheduled surgery…
The phase I/II study in patients with bladder cancer addresses the safety of our drug candidate Alpha1H and measures biomarkers of efficacy. The protocol is…
Dose-escalation studies have been performed to find the optimal dose of Alpha1H for future therapeutic studies. In the murine bladder cancer model, we observed a…
The Board of Hamlet Pharma AB has decided on a new date for the Annual General Meeting. The new date of the Annual General Meeting is Thursday,…